4//SEC Filing
BATOR MICHAEL G. 4
Accession 0001104659-25-005358
CIK 0001175151other
Filed
Jan 21, 7:00 PM ET
Accepted
Jan 22, 8:35 PM ET
Size
13.7 KB
Accession
0001104659-25-005358
Insider Transaction Report
Form 4
BATOR MICHAEL G.
Director
Transactions
- Exercise of In-Money
Common Stock
2025-01-17$1.00/sh+15,879$15,879→ 141,273 total - Exercise of In-Money
Subscription Rights (right to buy)
2025-01-17−15,879→ 0 totalExercise: $1.00From: 2024-12-09Exp: 2025-01-10→ Common Stock (15,879 underlying) - Other
Series A Right Warrants
2025-01-17+15,879→ 15,879 totalFrom: 2025-01-17Exp: 2025-02-24→ Common Stock (15,879 underlying) - Other
Series B Right Warrants
2025-01-17+15,879→ 15,879 totalFrom: 2025-01-17Exp: 2025-04-10→ Common Stock (15,879 underlying)
Footnotes (6)
- [F1]On January 17, 2025, the reporting person exercised certain subscription rights certificates received pursuant to a rights offering (the "Rights Offering") with CytoSorbents Corporation (the "Issuer") whereby the reporting person received Units consisting of an aggregate of 15,879 (i) shares of Issuer's common stock, par value $0.001 per share (the "Common Stock"), (ii) Series A Warrants to purchase one share of Common Stock, and (iii) Series B Warrants to purchase one share of Common Stock, at a subscription purchase price of $1.00 per unit for an aggregate cost of $15,879. The Rights Offering closed on January 10, 2025 (the "Closing Date").
- [F2]Includes (a) the following restricted stock units ("RSUs") which will vest upon a "Change of Control" of the Company, as defined in the CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (i) 3,300 RSUs granted on March 15, 2018, (ii) 6,000 RSUs granted on February 24, 2017, and (iii) 60,000 RSUs granted on June 7, 2016, and (b) 56,094 shares of Common Stock owned by the reporting person.
- [F3]The Series A Right Warrants exercise price shall be equal to 90% of the 5-day volume weighted average price of the Issuer's Common Stock over the 5-trading days prior to the expiration date of the Series A Right Warrants, rounded down to the nearest whole cent but (x) not lower than $1.00 and (y) not higher than $2.00.
- [F4]The Series A Right Warrants expire 45 calendar days following the Closing Date.
- [F5]The Series B Right Warrants exercise price shall be equal to 90% of the 5-day volume weighted average price of our Common Stock over the 5-trading days prior to the expiration date of the Series B Right Warrants, rounded down to the nearest whole cent but (x) not lower than $2.00 and (y) not higher than $4.00.
- [F6]The Series B Right Warrants expire 90 calendar days following the Closing Date.
Documents
Issuer
Cytosorbents Corp
CIK 0001175151
Entity typeother
Related Parties
1- filerCIK 0001647591
Filing Metadata
- Form type
- 4
- Filed
- Jan 21, 7:00 PM ET
- Accepted
- Jan 22, 8:35 PM ET
- Size
- 13.7 KB